Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Beta : -1.00 (As of May. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-05), Anebulo Pharmaceuticals's Beta is -1.00.

Anebulo Pharmaceuticals Beta Historical Data

The historical data trend for Anebulo Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Beta Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Beta

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beta	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Anebulo Pharmaceuticals's Beta

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Beta falls into.

Anebulo Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Anebulo Pharmaceuticals (NAS:ANEB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Anebulo Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

214:Germany

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Executives

Bimal R. Shah	director	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George	officer: Chief Financial Officer	1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner	officer: Acting Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen	director, officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English	director, 10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin	director	PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler	director, 10 percent owner	2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp	10 percent owner, other: See Explanation of Response	590 1ST AVE S, UNIT C1, SEATTLE WA 98104